(Updated - July 20, 2021 6:23 AM EDT)

Wedbush analyst Laura Chico downgraded Ardelyx, Inc (NASDAQ: ARDX) from Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades Hot Comments Hot Downgrades

Ardelyx's (ARDX) Shares Plunge as Tenapanor's Deficiencies Identified by FDA 'Take Approval Off the Table'July 20, 2021 9:57 AM Piper Sandler Downgrades Ardelyx, Inc (ARDX) to NeutralJuly 20, 2021 4:16 AM After-Hours Stock Movers 07/19: (AMRX) (CCK) (IBM) Higher; (ARDX) (RCUS) (PPG) Lower (more...)July 19, 2021 5:19 PM Form 8-K ARDELYX, INC. For: Jul 13July 19, 2021 4:24 PM Ardelyx (ARDX) to Resume Trading at 4:30 p.m.July 19, 2021 4:10 PM Ardelyx (ARDX) says FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments for Tenapanor at this timeJuly 19, 2021 4:02 PM Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on DialysisJuly 19, 2021 4:01 PM Ardelyx (ARDX) Halted, News PendingJuly 19, 2021 4:00 PM